SCHEMBL17257368

SCHEMBL17257368

C/C(=N\OS(=O)(=O)c1ccccc1)c1nc(C#N)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.41
KDM4E B2RXH2 6/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 9/20 0.39
MAPK1 P28482 2/20 0.36
XBP1 P17861 4/20 0.33
MPI P34949 4/20 0.33
NPSR1 Q6W5P4 4/20 0.33
HSP90AA1 P07900 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
RBBP9 O75884 1/20 0.32
CYP2C9 P11712 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2D6 P10635 1/20 0.32
GRM1 Q13255 1/20 0.32
LMNA P02545 4/20 0.32
S1PR2 O95136 3/20 0.32
HTT P42858 3/20 0.32
RAB9A P51151 2/20 0.32
PKM P14618 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17257372 1.00 ALDH1A1 (0.41) ALDH1A1KDM4EKMT2AMAPTMAPK1
SCHEMBL17257057 0.77 MAPT (0.33) ALDH1A1KMT2AMAPTRBBP9CYP2C9
SCHEMBL17257395 0.76 L3MBTL1 (0.51) ALDH1A1KDM4EKMT2AMAPTMAPK1
SCHEMBL17257663 0.74 CTDSP1 (0.39) ALDH1A1KDM4EKMT2AMAPTMAPK1
SCHEMBL17257664 0.74 CTDSP1 (0.39) ALDH1A1KDM4EKMT2AMAPTMAPK1
SCHEMBL17256744 0.74 RBBP9 (0.35) ALDH1A1KDM4EKMT2AMAPTRBBP9
SCHEMBL17256745 0.74 RBBP9 (0.35) ALDH1A1KDM4EKMT2AMAPTRBBP9
SCHEMBL213126 0.74 RBBP9 (0.59) ALDH1A1KDM4EKMT2AMAPTRBBP9
SCHEMBL17257202 0.73 ALDH1A1 (0.34) ALDH1A1KDM4EKMT2AMAPTMAPK1
SCHEMBL17257200 0.73 ALDH1A1 (0.34) ALDH1A1KDM4EKMT2AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
EP-3143055-B1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORP (JP) 2019-09-04 EP disclosed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB ALDH1A1 3041/4885KDM4E 1669/4885KMT2A 2399/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB ALDH1A1 3041/4885KDM4E 1669/4885KMT2A 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.